Buspirone/testosterone

Buspirone/testosterone
Combination of
Buspirone5-HT1A receptor agonist
TestosteroneAndrogen (ARTooltip androgen receptor agonist)
Clinical data
Other namesLybridos
Legal status
Legal status

Buspirone/testosterone (tentative brand name Lybridos) is a combination of buspirone, a 5-HT1A receptor partial agonist, α2-adrenergic receptor antagonist, and D2 autoreceptor antagonist,[1] and testosterone, an androgen or androgen receptor agonist, which is under development by the pharmaceutical company Emotional Brain for the treatment of female sexual dysfunction.[2][3] Both buspirone and testosterone have individually been found to be effective in the treatment of female sexual dysfunction in clinical studies, and so their combination could be anticipated to be even more effective.[4][5][6] As of January 2016, the combination is in phase II clinical trials, with a phase III trial being planned in the United States and Europe.[2]

See also

References

  1. ^ Loane C, Politis M (June 2012). "Buspirone: what is it all about?". Brain Research. 1461: 111–118. doi:10.1016/j.brainres.2012.04.032. PMID 22608068. S2CID 11734819.
  2. ^ a b "Buspirone/Testosterone - Emotional Brain". AdisInsight. Springer Nature Switzerland AG.
  3. ^ Meston CM, Stanton AM (2017). "Treatment of Female Sexual Interest/Arousal Disorder". In IsHak WW (ed.). The Textbook of Clinical Sexual Medicine. pp. 165–168. doi:10.1007/978-3-319-52539-6_11. ISBN 978-3-319-52538-9.
  4. ^ Goldstein I, Kim NN, Clayton AH, DeRogatis LR, Giraldi A, Parish SJ, et al. (January 2017). "Hypoactive Sexual Desire Disorder: International Society for the Study of Women's Sexual Health (ISSWSH) Expert Consensus Panel Review". Mayo Clinic Proceedings. 92 (1): 114–128. doi:10.1016/j.mayocp.2016.09.018. PMID 27916394.
  5. ^ Nappi RE, Cucinella L (April 2015). "Advances in pharmacotherapy for treating female sexual dysfunction". Expert Opinion on Pharmacotherapy. 16 (6): 875–887. doi:10.1517/14656566.2015.1020791. PMID 25732267. S2CID 24678911.
  6. ^ Bolour SY, Braunstein GD (September 2005). "Pharmacologic treatment options for hypoactive sexual desire disorder". Women's Health. 1 (2): 263–277. doi:10.2217/17455057.1.2.263. PMID 19803843.
Stub icon

This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by adding missing information.

Content Disclaimer

Informasi ini disarikan dari Wikipedia dan disajikan kembali untuk tujuan edukasi. Konten tersedia di bawah lisensi CC BY-SA 3.0. Kami tidak bertanggung jawab atas ketidakakuratan data yang bersumber dari kontribusi publik tersebut.

  1. The information displayed on this website is sourced in part or in whole from Wikipedia and has been adapted for the purpose of restating it. We strive to provide accurate and relevant information, however:
  2. There is no guarantee of absolute accuracy. Wikipedia is an open, collaborative project that can be edited by anyone, so information is subject to change.
  3. It is not intended to constitute professional advice. The content displayed is for informational and educational purposes only. For important decisions (e.g., medical, legal, or financial), please consult a professional.
  4. Content copyright. Wikipedia is licensed under the Creative Commons Attribution-ShareAlike License (CC BY-SA). This means that content may be reused with appropriate attribution and shared under a similar license.
  5. Responsible use. Any risk arising from the use of information from this website is entirely the responsibility of the user.